Awareness and use of quantitative decision-making methods in pharmaceutical development

Guido Thömmes,Martin Oliver Sailer,Nicolas Bonnet,Alex Carlton,Juan J. Abellan,Veronique Robert
DOI: https://doi.org/10.48550/arXiv.2203.00684
2022-03-01
Abstract:The pharmaceutical industry has experienced increasing costs and sustained high attrition rates in drug development over the last years. One proposal that addresses this challenge from a statistical perspective is the use of quantitative decision-making (QDM) methods to support a data-driven, objective appraisal of the evidence that forms the basis of decisions at different development levels. Growing awareness among statistical leaders in the industry has led to the creation of the European EFSPI/PSI special interest group (ESIG) on quantitative decision making to share experiences, collect best practices, and promote the use of QDM. In this paper, we introduce key components of QDM and present examples of QDM methods on trial, program, and portfolio level. The ESIG created a questionnaire to learn how and to what extent QDM methods are currently used in the different development phases. We present the main questionnaire findings, and we show where QDM is already used today but also where areas for future improvement can be identified. In particular, statisticians should increase their visibility, involvement, and leadership in cross-functional decision-making.
General Economics,Applications
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the issues of increasing costs and high failure rates faced by the pharmaceutical industry during the drug development process. Specifically, the authors propose the use of Quantitative Decision - Making (QDM) methods to support data - based, objective evidence evaluation, in order to form the basis for decision - making at different development stages. These methods aim to make decision - making more rational by providing a way to comprehensively evaluate the available evidence and its associated uncertainties, thereby increasing the success rate of drug development. The paper also explores the application of QDM methods at the trial, project, and portfolio levels, and uses questionnaires to understand the actual application of these methods in the pharmaceutical industry and the direction for future improvement.